Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Aging (Upcoming)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI119642

Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes.

M Kavallaris, D Y Kuo, C A Burkhart, D L Regl, M D Norris, M Haber, and S B Horwitz

Department of Molecular Pharmacology, Division of Gynecological Oncology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York 10461, USA.

Find articles by Kavallaris, M. in: JCI | PubMed | Google Scholar

Department of Molecular Pharmacology, Division of Gynecological Oncology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York 10461, USA.

Find articles by Kuo, D. in: JCI | PubMed | Google Scholar

Department of Molecular Pharmacology, Division of Gynecological Oncology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York 10461, USA.

Find articles by Burkhart, C. in: JCI | PubMed | Google Scholar

Department of Molecular Pharmacology, Division of Gynecological Oncology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York 10461, USA.

Find articles by Regl, D. in: JCI | PubMed | Google Scholar

Department of Molecular Pharmacology, Division of Gynecological Oncology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York 10461, USA.

Find articles by Norris, M. in: JCI | PubMed | Google Scholar

Department of Molecular Pharmacology, Division of Gynecological Oncology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York 10461, USA.

Find articles by Haber, M. in: JCI | PubMed | Google Scholar

Department of Molecular Pharmacology, Division of Gynecological Oncology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York 10461, USA.

Find articles by Horwitz, S. in: JCI | PubMed | Google Scholar

Published September 1, 1997 - More info

Published in Volume 100, Issue 5 on September 1, 1997
J Clin Invest. 1997;100(5):1282–1293. https://doi.org/10.1172/JCI119642.
© 1997 The American Society for Clinical Investigation
Published September 1, 1997 - Version history
View PDF
Abstract

The treatment of advanced ovarian cancer with taxol is hindered by the development of drug resistance. The cellular target for taxol is the microtubule that is stabilized by the drug. Taxol preferentially binds to the beta subunit of tubulin of which there are six distinct isotypes in mammalian cells. We have used highly specific oligonucleotides and polymerase chain reaction to analyze expression of all six beta-tubulin genes. Human lung cancer cells (A549) were selected in 12 and 24 nM taxol resulting in cell lines that were 9- and 17-fold resistant, respectively. These cells displayed an altered ratio of classes I, II, III, and IVa beta-tubulin isotypes. Ovarian tumors, seven untreated primary and four taxol- resistant tumor-bearing ascites, displayed significant increases (P < 0.005) in classes I (3.6-fold), III (4.4-fold), and IVa (7.6-fold) isotypes in the taxol-resistant samples as compared with untreated primary ovarian tumors. The increased expression appears to be related to the resistance phenotype, as the basal levels of the class III and IVa isotypes in the untreated tumors were extremely low. This is the first report of altered expression of specific beta-tubulin genes in taxol-resistant ovarian tumors and we propose that the latter may play a role in clinical resistance to taxol.

Version history
  • Version 1 (September 1, 1997): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts